Vyvanse (lisdexamfetamine)
People mainly take Vyvanse (lisdexamfetamine) for focus, mood. Based on 2 first-hand reports. Ranked #1960 of 1,974 overall.
5
User score
Mixed0% positive100% mixed0% negative0% unclear
Of reports that state an outcome, 0% are positive.
Clinical research
Research pending
What Vyvanse (lisdexamfetamine) does, according to users
Of the people who reported each effect, the share who said it got better.
betterno changeworse
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
Research data for Vyvanse (lisdexamfetamine) is being compiled.
Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
20 mgas reported
20 mgdaily
Reported side effects
How often each side effect came up across all reports.
numbness ×1irritability ×1agitation ×1compulsive sexual ×1
What users say
Verbatim quotes, shortened only — each links to the original discussion.
“at 20mg or 5mg life does feel much better. at anything over 20mg Vyvanse I feel uncomfortably numb, irritated and just mad at my existence.”
“great for my performance at work and overall executive functioning. The issue would be during the evenings and at home, I would 'lock-in' and masturbate for hours on end.”
Other options for focus
Retatrutide
Peptide · 298 reports
100% report better focus
Mostly positiveBResearch: Moderate
Caffeine + L-Theanine
Supplement · 46 reports
91% report better focus
Mostly positive
Creatine Monohydrate
Supplement · 139 reports
94% report better focus
Mostly positiveAResearch: Strong
Semaglutide
Medication · 137 reports
67% report better focus
Mostly positiveAResearch: Strong
Intermittent Fasting
Lifestyle · 171 reports
94% report better focus
Mostly positive
Magnesium Glycinate
Supplement · 910 reports
70% report better focus
Mostly positiveCResearch: Limited
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 2, 2026. How we rate